• About Us  
    • Our Mission
    • Company Profile
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • ProTcell platform
  • Pipeline
  • FAQ
  • News & Resources  
    • Press releases
    • Smart Stories
  • Partnering
  • Contact

Press Releases

All
Smart Stories
All
Press Releases
All
Factsheets

Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial

September 27, 2023

Smart Immune announces participation in leading scientific conferences

August 1, 2023

PRO-THYMUS: a groundbreaking solution to restore the immune system in AML patients, laureate of the Eurostars 3 program

July 11, 2023

Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)

May 11, 2023

Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform

April 17, 2023

Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator

March 30, 2023
Next
→
© 2021 Smart Immune SAS
Legal Notice
